Work

Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer

Year: 2023

Type: article

Abstract: Cancer of the prostate is the most common cancer occurring in men in the US. Despite advances in diagnosis and management, more than 34,000 men continue to die of prostate cancer each year in the United States.1 Androgen deprivation therapy (ADT) has been the standard of care for initial management of advanced or metastatic prostate cancer since Huggins and Hodges first introduced the concept of androgen-dependence. However, progression to metastatic castration-resistant prostate cancer (mCRPC) inevitably occurs after prolonged ADT.

Source: EBioMedicine

DOI: 10.1016/j.ebiom.2023.104756

Authors: Soha Bazyar, Philip Sutera, Matthew P. Deek, Catherine H. Marshall, Phuoc T. Tran

Institutions: University of Maryland, Baltimore, Johns Hopkins University, Johns Hopkins Medicine, Rutgers, The State University of New Jersey

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,000